Cargando…

Could ketamine be the answer to treating treatment-resistant major depressive disorder?

Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramadan, Abdullah Mohammed, Mansour, Islam Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437682/
https://www.ncbi.nlm.nih.gov/pubmed/32875273
http://dx.doi.org/10.1136/gpsych-2020-100227
_version_ 1783572667921596416
author Ramadan, Abdullah Mohammed
Mansour, Islam Ahmed
author_facet Ramadan, Abdullah Mohammed
Mansour, Islam Ahmed
author_sort Ramadan, Abdullah Mohammed
collection PubMed
description Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by the Food and Drug Administration in 2019, is a potential treatment option for those recalcitrant cases. The mechanism of ketamine is not fully understood, but as type it is classified as an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, and can be given intravenously, intranasally and orally. It is used to treat treatment-resistant depression, depression associated with suicidal ideation, mood and anxiety disorders and depressions associated with either type of bipolar disorder. Although ketamine is considered relatively safe, several side effects have been reported with the major ones being psychiatric in the form of worsening mood, anxiety and agitation; psychotomimetic in the form of dissociation, perceptual disturbance and abnormal sensations; cardiovascular in the form of increased blood pressure and increased heart rate; and neurological in the form of headache and dizziness. Ketamine is still not approved worldwide for usage in patients with treatment-resistant MDD, but if it is approved sometime in the future with relatively fewer side effects, it is expected to significantly save millions of dollars spent yearly on patients with treatment-resistant depression and that will lift this major burden off the shoulders of healthcare professionals. This study was designed to measure the effects of ketamine, an NMDA receptor antagonist, on patients with treatment-resistant MDD and to analyse the concept that makes it different and relatively safer than other major antidepressants like selective serotonin reuptake inhibitors, monoamine oxidase inhibitors and TCAs (tricyclic antidepressants).
format Online
Article
Text
id pubmed-7437682
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74376822020-08-31 Could ketamine be the answer to treating treatment-resistant major depressive disorder? Ramadan, Abdullah Mohammed Mansour, Islam Ahmed Gen Psychiatr Review Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by the Food and Drug Administration in 2019, is a potential treatment option for those recalcitrant cases. The mechanism of ketamine is not fully understood, but as type it is classified as an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, and can be given intravenously, intranasally and orally. It is used to treat treatment-resistant depression, depression associated with suicidal ideation, mood and anxiety disorders and depressions associated with either type of bipolar disorder. Although ketamine is considered relatively safe, several side effects have been reported with the major ones being psychiatric in the form of worsening mood, anxiety and agitation; psychotomimetic in the form of dissociation, perceptual disturbance and abnormal sensations; cardiovascular in the form of increased blood pressure and increased heart rate; and neurological in the form of headache and dizziness. Ketamine is still not approved worldwide for usage in patients with treatment-resistant MDD, but if it is approved sometime in the future with relatively fewer side effects, it is expected to significantly save millions of dollars spent yearly on patients with treatment-resistant depression and that will lift this major burden off the shoulders of healthcare professionals. This study was designed to measure the effects of ketamine, an NMDA receptor antagonist, on patients with treatment-resistant MDD and to analyse the concept that makes it different and relatively safer than other major antidepressants like selective serotonin reuptake inhibitors, monoamine oxidase inhibitors and TCAs (tricyclic antidepressants). BMJ Publishing Group 2020-08-18 /pmc/articles/PMC7437682/ /pubmed/32875273 http://dx.doi.org/10.1136/gpsych-2020-100227 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Ramadan, Abdullah Mohammed
Mansour, Islam Ahmed
Could ketamine be the answer to treating treatment-resistant major depressive disorder?
title Could ketamine be the answer to treating treatment-resistant major depressive disorder?
title_full Could ketamine be the answer to treating treatment-resistant major depressive disorder?
title_fullStr Could ketamine be the answer to treating treatment-resistant major depressive disorder?
title_full_unstemmed Could ketamine be the answer to treating treatment-resistant major depressive disorder?
title_short Could ketamine be the answer to treating treatment-resistant major depressive disorder?
title_sort could ketamine be the answer to treating treatment-resistant major depressive disorder?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437682/
https://www.ncbi.nlm.nih.gov/pubmed/32875273
http://dx.doi.org/10.1136/gpsych-2020-100227
work_keys_str_mv AT ramadanabdullahmohammed couldketaminebetheanswertotreatingtreatmentresistantmajordepressivedisorder
AT mansourislamahmed couldketaminebetheanswertotreatingtreatmentresistantmajordepressivedisorder